CIK 0001583648 · Non-accelerated filer<br>Smaller reporting company
PALVELLA THERAPEUTICS, INC.
Sign in to watch- Ticker
- PVLA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 300784346
- Phone
- (484) 253-1461
- Business address
- 353 W. LANCASTER AVENUE, SUITE 200, WAYNE, PA, 19087
- Former names
- PIERIS PHARMACEUTICALS, INC., Marika Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,725,861
- in 7 filings, $11.7M under 10b5-1 plans
Net −$11,725,861. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-17 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 | +2,148 | $9.08 | $20K | 4,302 |
| 2025-12-17 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 | −4,302 | $96.47 | $415K | 0 |
| 2025-12-17 | Goin Kathleen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,154 | 21,551 | ||
| 2025-12-17 | Goin Kathleen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,148 | 21,480 | ||
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 | +2,154 | $7.14 | $15K | 2,154 |
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Option exercise 10b5-1 | +2,148 | $9.08 | $20K | 4,302 |
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 | −1,500 | $85.72 | $129K | 2,802 |
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Sale 10b5-1 | −2,802 | $86.51 | $242K | 0 |
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,154 | 23,705 | ||
| 2025-11-19 | Goin Kathleen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,148 | 23,628 | ||
| 2025-06-10 | Wessel Tadd S. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,350 | 12,350 | ||
| 2025-06-10 | KIRITSY CHRISTOPHER P Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,350 | 12,350 | ||
| 2025-06-10 | JENKINS GEORGE M Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,350 | 12,350 | ||
| 2025-06-10 | HERON ELAINE J Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,350 | 12,350 | ||
| 2025-06-10 | Davis Todd C Director | Grant or award · Non-Qualified Stock Option (right to buy) | +12,350 | 12,350 | ||
| 2025-05-27 | Kline Ashley Hartmann Chief Commercial Officer | Grant or award · Incentive Stock Option (right to buy) | +17,436 | 17,436 | ||
| 2025-05-27 | Kline Ashley Hartmann Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +111,496 | 111,496 | ||
| 2025-04-09 | JENKINS GEORGE M Director | Purchase | +2,500 | $20.13 | $50K | 183,171 |
| 2025-04-09 | JENKINS GEORGE M Director | Purchase | +2,490 | $20.27 | $50K | 13,516 |
| 2025-02-05 | Kaupinen Wes President and CEO | Grant or award · Non-Qualified Stock Option (right to buy) | +243,831 | 243,831 |
Page 8 of 12 · 232 trades